Skip to main content

ORIGINAL RESEARCH article

Front. Mol. Biosci.
Sec. Metabolomics
Volume 11 - 2024 | doi: 10.3389/fmolb.2024.1406055
This article is part of the Research Topic Metabolomics in Personalized Cancer Medicine View all 3 articles

Exploring the Causal Role of Plasma Metabolites and Metabolite Ratios in Prostate Cancer: A Two-Sample Mendelian Randomization Study

Provisionally accepted
Changzhou Feng Changzhou Feng Haining Li Haining Li Chu Zhang Chu Zhang Ying Zhou Ying Zhou *Huanhuan Zhang Huanhuan Zhang *ping zheng ping zheng Shaolin Zhao Shaolin Zhao *Lei Wang Lei Wang *Jin Yang Jin Yang *
  • The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First Affiliated Hospital of Kangda College of Nanjing Medical University, lianyungang, China

The final, formatted version of the article will be published soon.

    Background: Prostate cancer (PCa), the most prevalent malignant neoplasm in males, involves complex biological mechanisms and risk factors, many of which remain unidentified. By employing a novel two-sample Mendelian randomization (MR) approach, this study aims to elucidate the causal relationships between the circulating metabolome and PCa risk, utilizing comprehensive data on genetically determined plasma metabolites and metabolite ratios. Methods: For the MR analysis, we utilized data from the GWAS Catalog database to analyze 1091 plasma metabolites and 309 ratios in relation to PCa outcomes within two independent GWAS datasets. The inverse variance weighted (IVW) method was the primary approach for determining the existence of the causal relationship, supplemented by additional MR methods for heterogeneity, pleiotropy, and cross-validation. The false discovery rate (FDR) and Bonferroni correction were applied to identify the most significant causative associations. Additionally, reverse MR and Steiger filtering were conducted to ascertain whether PCa influenced the observed metabolite levels. Furthermore, metabolic pathway analysis was conducted with MetaboAnalyst 6.0 software. Results: In the MR analysis, our findings reveal three overlapped metabolite ratios (arginine to glutamate, phosphate to uridine, and glycerol to mannitol/sorbitol) inversely associated with PCa risk. Following FDR correction (FDR < 0.05), cysteinylglycine disulfide was identified as a potential reducer of PCa risk, whereas Uridine and N-acetyl-L-glutamine (NAG) were pinpointed as potential risk factors. Notably, NAG (OR 1.044; 95% CI 1.025 to 1.063) emerged as a metabolite with significant causal influence, as confirmed by stringent Bonferroni correction (Pā€‰<ā€‰0.05/1400). Steiger's directionality test (Pā€‰<ā€‰0.001) and reverse MR confirmed the proposed causal direction. Furthermore, metabolic pathway analysis revealed a significant association between the "Glutathione Metabolism" pathway and PCa development. Conclusion: This study provides novel insights into the potential causal effects of plasma metabolites and metabolite ratios on PCa. The identified metabolites and ratios could serve as candidate biomarkers, contributing to the elucidation of PCa's biological mechanisms.

    Keywords: Metabolites, Metabolites ratios, prostate cancer (PCa), risk, Mendelian randomization (MR). 2

    Received: 24 Mar 2024; Accepted: 18 Dec 2024.

    Copyright: Ā© 2024 Feng, Li, Zhang, Zhou, Zhang, zheng, Zhao, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ying Zhou, The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First Affiliated Hospital of Kangda College of Nanjing Medical University, lianyungang, China
    Huanhuan Zhang, The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First Affiliated Hospital of Kangda College of Nanjing Medical University, lianyungang, China
    Shaolin Zhao, The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First Affiliated Hospital of Kangda College of Nanjing Medical University, lianyungang, China
    Lei Wang, The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First Affiliated Hospital of Kangda College of Nanjing Medical University, lianyungang, China
    Jin Yang, The First People's Hospital of Lianyungang, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First Affiliated Hospital of Kangda College of Nanjing Medical University, lianyungang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.